{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:54:27Z","timestamp":1793501667785,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001729","name":"Stiftelsen f\u00f6r\u00a0Strategisk Forskning","doi-asserted-by":"publisher","award":["RB13-0192"],"award-info":[{"award-number":["RB13-0192"]}],"id":[{"id":"10.13039\/501100001729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010815","name":"Stiftelsen f\u00f6r Gamla Tj\u00e4narinnor","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010815","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009673","name":"Gun och Bertil Stohnes Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009673","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gunvor och Josef An\u00e9rs stiftelsen"},{"name":"Loo och Hans Ostermans Stiftelse"},{"DOI":"10.13039\/100010823","name":"Tore Nilsons Stiftelse f\u00f6r Medicinsk Forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010823","id-type":"DOI","asserted-by":"publisher"}]},{"name":"KI Foundation for Geriatric Diseases"},{"name":"Demensfonden"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>MK6240 is a second-generation tau PET tracer designed to detect the neurofibrillary tangles in the brains of patients with Alzheimer\u2019s disease (AD). The aim of the study was to characterize <jats:sup>3<\/jats:sup>H-MK6240 in AD and control brain tissue and to compare its binding properties with those of first-generation tau PET tracers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Saturation binding assays with <jats:sup>3<\/jats:sup>H-MK6240 were carried out in the temporal and parietal cortices of AD brains to determine the maximum number of binding sites (Bmax) and the dissociation constants (Kd) at these sites. Competitive binding assays were carried out between <jats:sup>3<\/jats:sup>H-MK6240 and unlabelled MK6240, AV-1451 (aka T807, flortaucipir) and THK5117, and between <jats:sup>3<\/jats:sup>H-THK5351 and unlabelled MK6240. Regional binding studies with <jats:sup>3<\/jats:sup>H-MK6240 were carried out in homogenates from six AD and seven control brains and, using autoradiography, on large frozen sections from two AD brains and one control brain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The saturation binding assays gave Bmax and Kd values of 59.2\u00a0fmol\/mg and 0.32\u00a0nM in the temporal cortex and 154.7\u00a0fmol\/mg and 0.15\u00a0nM in the parietal cortex. The competitive binding assays revealed two binding sites with affinities in the picomolar and nanomolar range shared by <jats:sup>3<\/jats:sup>H-MK6240 and all the tested unlabelled compounds. There were no binding sites in common between <jats:sup>3<\/jats:sup>H-THK5351 and unlabelled MK6240. Regional binding of <jats:sup>3<\/jats:sup>H-MK6240 was significantly higher in AD brain tissue than in controls. Binding in brain tissue from AD patients with early-onset AD was significantly higher than in brain tissue from patients with late-onset AD. Binding of <jats:sup>3<\/jats:sup>H-MK6240 was not observed in off-target regions<jats:bold>.<\/jats:bold> Autoradiography showed high regional cortical binding in the two AD brains and very low binding in the control brain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p><jats:sup>3<\/jats:sup>H-MK6240 has a high binding affinity for tau deposits in AD brain tissue but also has different binding characteristics from those of the first-generation tau tracers. This confirms the complexity of tau tracer binding on tau deposits with different binding affinities for different binding sites.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-020-05035-y","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T04:02:23Z","timestamp":1600920143000},"page":"1093-1102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer\u2019s disease cases"],"prefix":"10.1007","volume":"48","author":[{"given":"Mona-Lisa","family":"Malarte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agneta","family":"Nordberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Lemoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"issue":"6","key":"5035_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/alzrt96","volume":"3","author":"A Nordberg","year":"2011","unstructured":"Nordberg A. Molecular imaging in Alzheimer\u2019s disease: new perspectives on biomarkers for early diagnosis and drug development. Alzheimers Res Ther. 2011;3(6):34.","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"5035_CR2","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1172\/JCI66029","volume":"123","author":"TE Golde","year":"2013","unstructured":"Golde TE, et al. Thinking laterally about neurodegenerative proteinopathies. J Clin Invest. 2013;123(5):1847\u201355.","journal-title":"J Clin Invest"},{"issue":"1","key":"5035_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S1474-4422(14)70252-2","volume":"14","author":"VL Villemagne","year":"2015","unstructured":"Villemagne VL, et al. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14(1):114\u201324.","journal-title":"Lancet Neurol"},{"issue":"7","key":"5035_CR4","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1039\/C7CS00706J","volume":"47","author":"P Verwilst","year":"2018","unstructured":"Verwilst P, et al. Shedding light on tau protein aggregation: the progress in developing highly selective fluorophores. Chem Soc Rev. 2018;47(7):2249\u201365.","journal-title":"Chem Soc Rev"},{"issue":"4","key":"5035_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40336-018-0290-y","volume":"6","author":"N Okamura","year":"2018","unstructured":"Okamura N, et al. The development and validation of tau PET tracers: current status and future directions. Clin Transl Imaging. 2018;6(4):305\u201316.","journal-title":"Clin Transl Imaging"},{"key":"5035_CR6","doi-asserted-by":"crossref","unstructured":"Leuzy A, et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry. 2019;24:1112\u201334","DOI":"10.1038\/s41380-018-0342-8"},{"issue":"1","key":"5035_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13024-017-0162-3","volume":"12","author":"L Saint-Aubert","year":"2017","unstructured":"Saint-Aubert L, et al. Tau PET imaging: present and future directions. Mol Neurodegener. 2017;12(1):19.","journal-title":"Mol Neurodegener"},{"key":"5035_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40478-015-0220-4","volume":"3","author":"L Lemoine","year":"2015","unstructured":"Lemoine L, et al. Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue. Acta Neuropathol Commun. 2015;3:40.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"5035_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13195-017-0325-z","volume":"9","author":"L Lemoine","year":"2017","unstructured":"Lemoine L, et al. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. Alzheimers Res Ther. 2017;9(1):96.","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"5035_CR10","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s00259-018-4012-5","volume":"45","author":"K Chiotis","year":"2018","unstructured":"Chiotis K, et al. Dual tracer tau PET imaging reveals different molecular targets for (11)C-THK5351 and (11)C-PBB3 in the Alzheimer brain. Eur J Nucl Med Mol Imaging. 2018;45(9):1605\u201317.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7662","key":"5035_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature23002","volume":"547","author":"AWP Fitzpatrick","year":"2017","unstructured":"Fitzpatrick AWP, et al. Cryo-EM structures of tau filaments from Alzheimer\u2019s disease. Nature. 2017;547(7662):185\u201390.","journal-title":"Nature"},{"key":"5035_CR12","doi-asserted-by":"publisher","first-page":"45496","DOI":"10.1038\/srep45496","volume":"7","author":"L Lemoine","year":"2017","unstructured":"Lemoine L, et al. Cortical laminar tau deposits and activated astrocytes in Alzheimer\u2019s disease visualised by (3)H-THK5117 and (3)H-deprenyl autoradiography. Sci Rep. 2017;7:45496.","journal-title":"Sci Rep"},{"issue":"2","key":"5035_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/mds.27271","volume":"33","author":"C Vermeiren","year":"2018","unstructured":"Vermeiren C, et al. The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. Mov Disord. 2018;33(2):273\u201381.","journal-title":"Mov Disord"},{"issue":"1","key":"5035_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s13311-016-0490-y","volume":"14","author":"JR Brosch","year":"2017","unstructured":"Brosch JR, et al. Tau imaging in Alzheimer\u2019s disease diagnosis and clinical trials. Neurotherapeutics. 2017;14(1):62\u20138.","journal-title":"Neurotherapeutics"},{"issue":"7","key":"5035_CR15","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/mds.27029","volume":"32","author":"A Perez-Soriano","year":"2017","unstructured":"Perez-Soriano A, et al. PBB3 imaging in Parkinsonian disorders: evidence for binding to tau and other proteins. Mov Disord. 2017;32(7):1016\u201324.","journal-title":"Mov Disord"},{"issue":"2","key":"5035_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11682-018-9847-7","volume":"13","author":"C Lois","year":"2019","unstructured":"Lois C, et al. PET imaging of tau protein targets: a methodology perspective. Brain Imaging Behav. 2019;13(2):333\u201344.","journal-title":"Brain Imaging Behav"},{"issue":"12","key":"5035_CR17","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.2967\/jnumed.118.214437","volume":"59","author":"H Kuwabara","year":"2018","unstructured":"Kuwabara H, et al. Evaluation of (18)F-RO-948 PET for quantitative assessment of tau accumulation in the human brain. J Nucl Med. 2018;59(12):1877\u201384.","journal-title":"J Nucl Med"},{"issue":"10","key":"5035_CR18","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1007\/s00259-019-04397-2","volume":"46","author":"H Kroth","year":"2019","unstructured":"Kroth H, et al. Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer\u2019s disease and other tauopathies. Eur J Nucl Med Mol Imaging. 2019;46(10):2178\u201389.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"5035_CR19","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2967\/jnumed.116.185199","volume":"58","author":"L Declercq","year":"2017","unstructured":"Declercq L, et al. Preclinical evaluation of (18)F-JNJ64349311, a novel PET tracer for tau imaging. J Nucl Med. 2017;58(6):975\u201381.","journal-title":"J Nucl Med"},{"issue":"5","key":"5035_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/jlcr.3496","volume":"60","author":"TL Collier","year":"2017","unstructured":"Collier TL, et al. cGMP production of the radiopharmaceutical [(18) F]MK-6240 for PET imaging of human neurofibrillary tangles. J Labelled Comp Radiopharm. 2017;60(5):263\u20139.","journal-title":"J Labelled Comp Radiopharm"},{"issue":"10","key":"5035_CR21","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2967\/jnumed.115.171678","volume":"57","author":"ED Hostetler","year":"2016","unstructured":"Hostetler ED, et al. Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med. 2016;57(10):1599\u2013606.","journal-title":"J Nucl Med"},{"issue":"10","key":"5035_CR22","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1021\/acs.jmedchem.6b00166","volume":"59","author":"AM Walji","year":"2016","unstructured":"Walji AM, et al. Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): a positron emission tomography (PET) imaging agent for quantification of neurofibrillary tangles (NFTs). J Med Chem. 2016;59(10):4778\u201389.","journal-title":"J Med Chem"},{"issue":"6","key":"5035_CR23","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00259-019-04305-8","volume":"46","author":"NA Murugan","year":"2019","unstructured":"Murugan NA, et al. Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. Eur J Nucl Med Mol Imaging. 2019;46(6):1369\u201382.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"5035_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40478-019-0686-6","volume":"7","author":"C Aguero","year":"2019","unstructured":"Aguero C, et al. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathol Commun. 2019;7(1):37.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"5035_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2967\/jnumed.118.208215","volume":"60","author":"TG Lohith","year":"2019","unstructured":"Lohith TG, et al. Brain imaging of Alzheimer dementia patients and elderly controls with (18)F-MK-6240, a PET tracer targeting neurofibrillary tangles. J Nucl Med. 2019;60(1):107\u201314.","journal-title":"J Nucl Med"},{"key":"5035_CR26","doi-asserted-by":"crossref","unstructured":"Pascoal TA, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020;143(9): 2818\u201330.","DOI":"10.1093\/brain\/awaa180"},{"issue":"7","key":"5035_CR27","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1021\/acschemneuro.8b00093","volume":"9","author":"NA Murugan","year":"2018","unstructured":"Murugan NA, Nordberg A, Agren H. Different positron emission tomography tau tracers bind to multiple binding sites on the tau fibril: insight from computational modeling. ACS Chem Neurosci. 2018;9(7):1757\u201367.","journal-title":"ACS Chem Neurosci"},{"issue":"9","key":"5035_CR28","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1093\/brain\/awx171","volume":"140","author":"M Scholl","year":"2017","unstructured":"Scholl M, et al. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer\u2019s disease. Brain. 2017;140(9):2286\u201394.","journal-title":"Brain"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-05035-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-020-05035-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-05035-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T06:52:44Z","timestamp":1632466364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-020-05035-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["5035"],"URL":"https:\/\/doi.org\/10.1007\/s00259-020-05035-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,24]]},"assertion":[{"value":"6 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted according to the principles of the Declaration of Helsinki and subsequent revisions. All experiments on autopsied human brain tissue were carried out in accordance with ethical permission obtained from the regional human ethics committee in Stockholm (permission number 2011\/962\/31-1), and the medical ethics committee of the VU Medical Center for the Netherlands Brain Bank tissue (permission number 1998-06\/5).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Previous consent to carry out experiments was given at the time of brain donation, and no supplementary consent was needed for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Previous consent to publish the results of experiments was given at the time of brain donation, and no supplementary consent was needed for this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}